Literature DB >> 24898801

Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant.

Sarah L Sammons1, Keith W Pratz, B Douglas Smith, Judith E Karp, Ashkan Emadi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24898801      PMCID： PMC4144402          DOI： 10.1002/ajh.23782

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  13 in total

1.  Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.

Authors:  Sung Ho Lee; Elisabeth Paietta; Janis Racevskis; Peter H Wiernik
Journal:  Am J Hematol       Date:  2009-10       Impact factor: 10.047

Review 2.  FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

Authors:  Mark Levis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

3.  Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.

Authors:  Gautam Borthakur; Hagop Kantarjian; Farhad Ravandi; Weiguo Zhang; Marina Konopleva; John J Wright; Stefan Faderl; Srdan Verstovsek; Sheela Mathews; Michael Andreeff; Jorge E Cortes
Journal:  Haematologica       Date:  2010-10-15       Impact factor: 9.941

Review 4.  FLT3: ITDoes matter in leukemia.

Authors:  M Levis; D Small
Journal:  Leukemia       Date:  2003-09       Impact factor: 11.528

5.  Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Authors:  Farhad Ravandi; Mona Lisa Alattar; Michael R Grunwald; Michelle A Rudek; Trivikram Rajkhowa; Mary Ann Richie; Sherry Pierce; Naval Daver; Guillermo Garcia-Manero; Stefan Faderl; Aziz Nazha; Marina Konopleva; Gautam Borthakur; Jan Burger; Tapan Kadia; Sara Dellasala; Michael Andreeff; Jorge Cortes; Hagop Kantarjian; Mark Levis
Journal:  Blood       Date:  2013-04-23       Impact factor: 22.113

6.  Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.

Authors:  Stephan Metzelder; Ying Wang; Ellen Wollmer; Michael Wanzel; Sabine Teichler; Anuhar Chaturvedi; Martin Eilers; Erich Enghofer; Andreas Neubauer; Andreas Burchert
Journal:  Blood       Date:  2009-04-23       Impact factor: 22.113

7.  Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.

Authors:  N N Safaian; A Czibere; I Bruns; R Fenk; P Reinecke; A Dienst; R Haas; G Kobbe
Journal:  Leuk Res       Date:  2008-06-24       Impact factor: 3.156

8.  A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.

Authors:  Michael Crump; David Hedley; Suzanne Kamel-Reid; Brian Leber; Richard Wells; Joseph Brandwein; Rena Buckstein; Janine Kassis; Mark Minden; John Matthews; Sue Robinson; Robert Turner; Lynn McIntosh; Elizabeth Eisenhauer; Lesley Seymour
Journal:  Leuk Lymphoma       Date:  2010-02

9.  A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.

Authors:  K W Pratz; E Cho; M J Levis; J E Karp; S D Gore; M McDevitt; A Stine; M Zhao; S D Baker; M A Carducci; J J Wright; M A Rudek; B D Smith
Journal:  Leukemia       Date:  2010-06-10       Impact factor: 11.528

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
View more
  14 in total

1.  Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.

Authors:  Andrew M Brunner; Shuli Li; Amir T Fathi; Martha Wadleigh; Vincent T Ho; Kerry Collier; Christine Connolly; Karen K Ballen; Corey S Cutler; Bimalangshu R Dey; Areej El-Jawahri; Sarah Nikiforow; Steven L McAfee; John Koreth; Daniel J Deangelo; Edwin P Alyea; Joseph H Antin; Thomas R Spitzer; Richard M Stone; Robert J Soiffer; Yi-Bin Chen
Journal:  Br J Haematol       Date:  2016-07-19       Impact factor: 6.998

2.  The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia.

Authors:  Yanhua Yue; Song Jin; Ting Xu; Jin Zhou; Liang Ma; Hongjie Shen; Depei Wu; Suning Chen; Miao Miao
Journal:  Indian J Hematol Blood Transfus       Date:  2015-08-28       Impact factor: 0.900

Review 3.  Life after transplant: are we becoming high maintenance in AML?

Authors:  A M Brunner; A T Fathi; Y B Chen
Journal:  Bone Marrow Transplant       Date:  2016-06-20       Impact factor: 5.483

4.  How I treat FLT3-mutated AML.

Authors:  Keith W Pratz; Mark Levis
Journal:  Blood       Date:  2016-11-21       Impact factor: 22.113

Review 5.  Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Authors:  Robert J Soiffer; Yi-Bin Chen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 6.  Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Authors:  Robert J Soiffer; Yi-Bin Chen
Journal:  Blood Adv       Date:  2017-11-28

7.  A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.

Authors:  Keith W Pratz; Michelle A Rudek; B Douglas Smith; Judith Karp; Ivana Gojo; Amy Dezern; Richard J Jones; Jackie Greer; Christopher Gocke; Maria R Baer; Vu H Duong; Gary Rosner; Marianna Zahurak; John J Wright; Ashkan Emadi; Mark Levis
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-21       Impact factor: 5.742

8.  Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.

Authors:  Marissa A Zarakas; Jigar V Desai; Georgios Chamilos; Michail S Lionakis
Journal:  Curr Fungal Infect Rep       Date:  2019-07-05

9.  Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.

Authors:  Nestor R Ramos; Clifton C Mo; Judith E Karp; Christopher S Hourigan
Journal:  J Clin Med       Date:  2015-04       Impact factor: 4.241

10.  High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.

Authors:  Hsiao-Wen Kao; D Cherng Liang; Ming-Chung Kuo; Jin-Hou Wu; Po Dunn; Po-Nan Wang; Tung-Liang Lin; Yu-Shu Shih; Sung-Tzu Liang; Tung-Huei Lin; Chen-Yu Lai; Chun-Hui Lin; Lee-Yung Shih
Journal:  Oncotarget       Date:  2015-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.